Dear Ms. Parsi:

Please refer to your Supplemental New Drug Applications (sNDA) dated January 17, 2007, September 30, 2008, and March 8, 2010, respectively, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for THALOMID® (thalidomide) 50mg, 100mg, 150mg, 200mg Capsules.

We acknowledge receipt of your amendments dated November 1, 2010; February 11, April 1 and 22, and May 9, 2011, and January 4, 2012.

“Changes Being Effected” supplemental new drug application S-035 provides for revisions to the carton and blister card labeling for THALOMID 50 mg, 100 mg, and 200 mg Capsules.

“Prior Approval” supplemental new drug application S-040 provides for updates to the package insert based upon the THAL-MM-003 trial “A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study of Combination Thalidomide Plus Dexamethasone Therapy Versus Dexamethasone Therapy Alone As Induction Therapy For Previously Untreated Subjects With Multiple Myeloma” and conversion of the labeling to comply with the Physician’s Labeling Rule. Trial THAL-MM-003 is one of two required postmarketing commitments outlined in our May 25, 2006 letter for the Accelerated Approval (under 21 CFR 314.510) for the treatment of patients with newly diagnosed multiple myeloma.

“Changes Being Effected” supplemental new drug application S-043 provides for the addition of a unit dose packaging for the THALOMID 50 mg capsule.

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA
automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling with the addition of any labeling changes in pending “Changes Being Effecte” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for content of Labeling Technical Qs and As” at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

CARTON AND IMMEDIATE CONTAINER LABELS

Submit final printed carton and container labels that are identical to the carton and immediate container labels submitted on September 15, 2011, as soon as they are available, but no more than 30 days after they are printed.

Please submit these labels electronically according to the guidance for industry titled “Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008).” Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “Product Correspondence – Final Printed Carton and Container Labels for approved NDA 020785/S-035/S-040/S-043.” Approval of this submission by FDA is not required before the labeling is used.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.
Because this drug product for this indication has an orphan drug designation, you are exempt from this requirement.

**POSTMARKETING COMMITMENTS SUBJECT TO REPORTING REQUIREMENTS UNDER SECTION 506B**

Products approved under the accelerated approval regulations, 21 CFR 314.510, require further adequate and well-controlled studies/clinical trials to verify and describe clinical benefit. We remind you that there is a required postmarketing commitment (An Epidemiology Study of Venous Thrombotic Events in Thalidomide Treated Multiple Myeloma Patients) listed in the May 25, 2006 approval letter that is still open.

**PROMOTIONAL MATERIALS**

As a reminder and as required by 21 CFR 314.550, submit all promotional materials at least 30 days before the intended time of initial distribution of labeling or initial publication of the advertisement. Send two copies of all promotional materials directly to:

- Food and Drug Administration
- Center for Drug Evaluation and Research
- Office of Prescription Drug Promotion (OPDP)
- 5901-B Ammendale Road
- Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at [http://www.fda.gov/opacom/morechoices/fdaforms/cder.html](http://www.fda.gov/opacom/morechoices/fdaforms/cder.html); instructions are provided on page 2 of the form. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see [http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm](http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm).

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).
If you have any questions, call Amy Baird, Regulatory Project Manager, at (301) 796-4969.

Sincerely,

{See appended electronic signature page}

Robert L. Justice, M.D., M.S.
Director
Division of Oncology Products 1
Office of Hematology and Oncology Products
Center for Drug Evaluation and Research

ENCLOSURE(S):
  Content of Labeling
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ROBERT L JUSTICE
02/03/2012